Haplomics

Biotech · Defunct

Viral-free gene therapy to restore endogenous Factor VIII expression in hemophilia A patients by repairing the intron 22 inversion mutation

Grants
$467K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
10
1 granted · 9 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · Strategies for Personalized Gene Repair using I22I Severe Hemophilia-A as a Model$233,500
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · Strategies for Personalized Gene Repair using I22I Severe Hemophilia-A as a Model$233,500
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3247TARGEAD SCIENCES, INC.——
3248SYMBIOTICA, INC.——
3249SCI-ENGI-MEDCO SOLUTIONS, INC——
3250Haplomics——
3251MBC PHARMA, INC.——
3252OM BHARTI LLC——
3253Percept Corp—$4.8M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 10
  • Allelic Variants Of Human Factor Viiigranted
  • Predicting And Reducing Alloimmunogenicity Of Protein Therapeuticsapplication
  • Allelic Variants Of Human Factor Viiiapplication
  • Compositions and Methods for Treating Hemophiliaapplication
  • Predicting And Reducing Alloimmunogenicity Of Protein Therapeuticsapplication
  • Compositions And Methods Of Treatment Of Black Hemophiliac Patientsapplication
  • Allelic Variants Of Human Factor Viiiapplication
  • F8 Gene Repairapplication
  • F8 Gene Repairapplication
  • F8 gene repairapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.